The association between benzodiazepine co-prescription, opioid agonist treatment and mortality: a systematic review.

Autor: Hestevik CH; The Norwegian Institute of Public Health, Postboks 222 Skøyen, Oslo, 0213, Norway. chhe@fhi.no., Evensen LH; The Norwegian Institute of Public Health, Postboks 222 Skøyen, Oslo, 0213, Norway., Kornør H; The Norwegian Institute of Public Health, Postboks 222 Skøyen, Oslo, 0213, Norway., Skeie I; National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Department of Mental Health, Innlandet Hospital Trust, P.O. Box 104, Brumunddal, 2381, Norway.
Jazyk: angličtina
Zdroj: BMC psychiatry [BMC Psychiatry] 2024 Oct 28; Vol. 24 (1), pp. 741. Date of Electronic Publication: 2024 Oct 28.
DOI: 10.1186/s12888-024-06191-3
Abstrakt: Background: Opioid agonist treatment (OAT) is the preferred treatment for opioid dependence due to benefits such as treatment retention, reduced opioid use and mortality. Benzodiazepine co-dependence is common in OAT patients and has been linked to increased mortality. Prescribing benzodiazepines during OAT has been tried to reduce the harms of extra-medical benzodiazepine use. This systematic review examines association between benzodiazepine co-prescription during OAT and mortality.
Methods: We searched MEDLINE, Embase, Psych INFO, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and Epistemonikos for reports published from database inception to June 2021. The searches were updated in February 2024. We included studies comparing mortality rates in OAT patients with and without benzodiazepine co-prescription. Two reviewers independently screened, extracted data, and assessed risk of bias from eligible studies with the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. We combined the effect estimates in meta-analyses where possible. The certainty of the pooled effect estimates was assessed using the GRADE approach.
Results: We included six observational studies (N = 84,452) conducted in Sweden, Scotland, Canada, England, and the USA. Moderate-certainty evidence linked benzodiazepine prescription to higher all-cause mortality on OAT (HR 1.83; 95% CI 1.59 to 2.11). Moderate-certainty evidence associated benzodiazepine prescription with higher non-drug-induced mortality during OAT and the whole observation period (HR 1.73; 95% CI 1.33 to 2.25) and HR 2.02; 95% CI 1.29 to 3.18). Low-certainty evidence suggested an association with higher drug-induced mortality on OAT (HR 2.36; 95% CI 1.38 to 4.0). Very low-certainty evidence linked benzodiazepine prescription to higher all-cause and drug-induced mortality throughout the observation period (HR 1.49; 95% CI 1.02 to 2.18 and HR 2.19; 95% CI 0.80 to 6.0).
Conclusions: There is probably an association between prescribed benzodiazepine use and higher risk of all-cause mortality (on OAT) and mortality due to non-drug-induced causes (on OAT and on and off OAT). Benzodiazepine prescription may also be associated with higher all-cause mortality (on and off OAT) and drug-induced mortality (on OAT and on and off-OAT), but this is highly uncertain due to methodological issues and possible confounding.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: